Copy to clipboard 
Smith+Nephew reported 1Q25 orthopedic sales of $971.4 million, up 1.2% compared to the first quarter of 2024.
The company drove double-digit growth from CORI, the EVOS plating system and Regeneten during the first quarter.
Knee (+0.9%) and hip (+2%) sales in the U.S. improved on a days-adjusted basis but still remain well below market growth. Outside the U.S., headwinds in China totaled around 4% in knees and 7% in hips.
EVOS continued its momentum, driven by EVOS Large and Periprosthetic, while the AETOS Shoulder system increased its contribution to growth in the quarter.
Smith+Nephew’s sports medicine business was impacted by the implementation of volume-based procurement in China, equating to a 7.7% headwind on joint repair products and 3.4% headwind on arthroscopic enabling technology.
All told, the company’s first quarter performance was in line with its expectations. Its guidance, total underlying revenue growth of 5%, remains unchanged.
The company generated 54% of its revenue in the United States in 2024, with two-thirds of that sold product manufactured in the United States. The company’s 2025 outlook estimates tariff impact between $15 million and $20 million based on currently-announced measures.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $418.3 | $422.3 | ($4.0) | (1%) |
| Knees | $246.6 | $247.8 | ($1.2) | (0.5%) |
| Hips | $150.8 | $155.1 | ($4.3) | (2.8%) |
| Extremities | $20.9 | $19.4 | $1.5 | 7.5% |
| Trauma | $133.6 | $127.0 | $6.6 | 5.2% |
| Sports Medicine | $393.4 | $392.8 | $0.6 | 0.2% |
| Enabling Technology | $26.0 | $18.0 | $8.0 | 44.4% |
| Total | $971.4 | $960.2 | $11.2 | 1.2% |
Orthopedic Sales by Geography
| Region | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $524.0 | $507.8 | $16.2 | 3.2% |
| OUS | $447.4 | $452.4 | ($5.0) | (1.1%) |
| EMEA | $260.9 | $256.0 | $4.8 | 1.9% |
| APAC | $80.2 | $88.2 | ($7.9) | (9%) |
| ROW | $106.2 | $108.2 | ($1.9) | (1.8%) |
| Total | $971.4 | $960.2 | $11.2 | 1.2% |
Smith+Nephew reported 1Q25 orthopedic sales of $971.4 million, up 1.2% compared to the first quarter of 2024.
The company drove double-digit growth from CORI, the EVOS plating system and Regeneten during the first quarter.
Knee (+0.9%) and hip (+2%) sales in the U.S. improved on a days-adjusted basis but still remain well below market...
Smith+Nephew reported 1Q25 orthopedic sales of $971.4 million, up 1.2% compared to the first quarter of 2024.
The company drove double-digit growth from CORI, the EVOS plating system and Regeneten during the first quarter.
Knee (+0.9%) and hip (+2%) sales in the U.S. improved on a days-adjusted basis but still remain well below market growth. Outside the U.S., headwinds in China totaled around 4% in knees and 7% in hips.
EVOS continued its momentum, driven by EVOS Large and Periprosthetic, while the AETOS Shoulder system increased its contribution to growth in the quarter.
Smith+Nephew’s sports medicine business was impacted by the implementation of volume-based procurement in China, equating to a 7.7% headwind on joint repair products and 3.4% headwind on arthroscopic enabling technology.
All told, the company’s first quarter performance was in line with its expectations. Its guidance, total underlying revenue growth of 5%, remains unchanged.
The company generated 54% of its revenue in the United States in 2024, with two-thirds of that sold product manufactured in the United States. The company’s 2025 outlook estimates tariff impact between $15 million and $20 million based on currently-announced measures.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $418.3 | $422.3 | ($4.0) | (1%) |
| Knees | $246.6 | $247.8 | ($1.2) | (0.5%) |
| Hips | $150.8 | $155.1 | ($4.3) | (2.8%) |
| Extremities | $20.9 | $19.4 | $1.5 | 7.5% |
| Trauma | $133.6 | $127.0 | $6.6 | 5.2% |
| Sports Medicine | $393.4 | $392.8 | $0.6 | 0.2% |
| Enabling Technology | $26.0 | $18.0 | $8.0 | 44.4% |
| Total | $971.4 | $960.2 | $11.2 | 1.2% |
Orthopedic Sales by Geography
| Region | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $524.0 | $507.8 | $16.2 | 3.2% |
| OUS | $447.4 | $452.4 | ($5.0) | (1.1%) |
| EMEA | $260.9 | $256.0 | $4.8 | 1.9% |
| APAC | $80.2 | $88.2 | ($7.9) | (9%) |
| ROW | $106.2 | $108.2 | ($1.9) | (1.8%) |
| Total | $971.4 | $960.2 | $11.2 | 1.2% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
